First AD

Second AD

Emerging Data and Treatment Considerations in HER2 Ultralow Breast Cancer

Video content above is prompted by the following:

Briefly discuss how you approach treatment for patients with 

How does your treatment strategy for patients with HER2-ultralow breast cancer differ from your approach in patients with HER2-positive and HER2-low status?

Are you currently implementing the DESTINY-Breast06 regimen in your clinical practice for patients with HER2 ultra-low breast cancer? If so, please elaborate on patient selection and sequencing.

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Recent Advances in the Treatment of Advanced   HER2+ Breast Cancer: SABCS 2024 

Peer Exchange

Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences.